Literature DB >> 15302515

Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture.

A Qian1, R A Meals, J Rajfer, N F Gonzalez-Cadavid.   

Abstract

OBJECTIVES: To compare the gene expression alterations in human Peyronie's disease (PD) and Dupuytren's disease (DD) to determine whether they share a common pathophysiology. Multiple mRNA expression profiles of human PD have previously shown that genes that regulate fibroblast replication, myofibroblast differentiation, collagen metabolism, tissue repair, and ossification are involved. DD, a palmar fascia fibrosis, may be associated with PD.
METHODS: Total RNA samples from PD plaques, normal tunica albuginea, Dupuytren's nodules, and normal palmar fascia (nine samples per group) were subjected to differential gene expression profile analysis (Clontech Atlas DNA microarray) comparing PD with tunica albuginea and DD with normal palmar fascia. Changes of more than 2.0 in PD and DD compared with tunica albuginea and normal palmar fascia, respectively, were recorded. Reverse transcriptase-polymerase chain reactions were performed for some genes whose expression was altered in PD.
RESULTS: Some of the gene families upregulated in both PD and DD were (a) collagen degradation: matrix metalloproteinase (MMP), with MMP2 and MMP9, and thymosins (MMP activators), with TMbeta10 and TMbeta4; (b) ossification: osteoblast-specific factors (OSFs) OSF-1 and OSF-2 (DD only); and (c) myofibroblast differentiation: RhoGDP dissociation inhibitor 1. The genes upregulated in PD only were decorin (an inhibitor of transforming growth factor-beta1 and a part of fibroblast replication/collagen synthesis) and early growth response protein. Reverse transcriptase-polymerase chain reaction confirmed these changes.
CONCLUSIONS: These data demonstrate that the pattern of alterations in the expression of certain gene families in PD and DD is similar, suggesting that they share a common pathophysiology and may be amenable to the same therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302515     DOI: 10.1016/j.urology.2004.04.006

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  32 in total

1.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

Review 2.  The fascia of the limbs and back--a review.

Authors:  Mike Benjamin
Journal:  J Anat       Date:  2009-01       Impact factor: 2.610

3.  The potential roles of cell migration and extra-cellular matrix interactions in Dupuytren's disease progression and recurrence.

Authors:  Linda Vi; Bing Siang Gan; David B O'Gorman
Journal:  Med Hypotheses       Date:  2009-11-05       Impact factor: 1.538

Review 4.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

Review 5.  Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects.

Authors:  María Alejandra Egui Rojo; Ignacio Moncada Iribarren; Joaquín Carballido Rodriguez; Juan Ignacio Martinez-Salamanca
Journal:  Ther Adv Urol       Date:  2014-10

6.  Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.

Authors:  Syed Amir Iqbal; Christopher Manning; Farhatullah Syed; Venkatesh Kolluru; Mike Hayton; Stewart Watson; Ardeshir Bayat
Journal:  Stem Cells Dev       Date:  2011-07-19       Impact factor: 3.272

7.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

8.  The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Authors:  Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2014-12-11       Impact factor: 3.802

9.  Molecular mechanisms and treatment strategies for Dupuytren's disease.

Authors:  David B O'Gorman; Linda Vi; Bing Siang Gan
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

10.  Type-1 Collagen differentially alters beta-catenin accumulation in primary Dupuytren's Disease cord and adjacent palmar fascia cells.

Authors:  Linda Vi; Anna Njarlangattil; Yan Wu; Bing Siang Gan; David B O'Gorman
Journal:  BMC Musculoskelet Disord       Date:  2009-06-19       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.